SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Donald J. Santel, Chief Executive Officer, will provide a company overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on Monday, May 15 at 12:40pm CEST in Monte Carlo, Monaco.
To access the live webcast, please go to www.cotherix.com and click on the “Investor Relations” link. The replay will be available for approximately one week following the presentation.
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix markets Ventavis(R) (iloprost) Inhalation Solution in the United States for the treatment of pulmonary arterial hypertension (PAH) in patients with NYHA Class III or IV symptoms (World Health Organization Group I). PAH is a highly debilitating and potentially fatal disease characterized by high blood pressure in the pulmonary arteries of the lungs. Ventavis is an inhaled formulation of iloprost, a synthetic compound that is structurally similar to prostacyclins. CoTherix, the CoTherix logo and the REVEAL Registry are trademarks of CoTherix, Inc. Ventavis is a trademark of Schering AG, Germany. More information can be found at www.cotherix.com and www.4Ventavis.com.
CoTherix, Inc.
CONTACT: investors and media, Anne Bowdidge, Senior Director of InvestorRelations of CoTherix, Inc., +1-650-808-6551
